Taurolidine-citrate lock solution for prevention of endoluminal central venous catheter infection in neutropenic hematological patients: a randomized, double-blind, placebo-controlled trial (TAURCAT).

Conclusions: In this trial involving high-risk patients carrying non-tunnelled CVCs, the use of taurolidine-citrate-heparin did not show benefit over placebo. Nevertheless, the safety of this prevention strategy and the trend towards less hub colonization in the taurolidine-citrate-heparin group raise the interest in assessing its efficacy in centers with higher rates of CRBSI.
PMID: 31712211 [PubMed - as supplied by publisher]

Source: Antimicrobial Agents and Chemotherapy - November 10, 2019 Category: Microbiology Authors: Gudiol C, Arnan M, Aguilar-Guisado M, Royo-Cebrecos C, Sánchez-Ortega I, Montero I, Martín-Gandul C, Laporte-Amargós J, Albasanz-Puig A, Nicolae S, Perayre M, Berbel D, Tebe C, Riera J, Sureda A, Cisneros JM, Carratalà J Tags: Antimicrob Agents Chemother Source Type: research